Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics

Shannon L Carpenter, Martin Chandler, Michael F Guerrera, Lynn Malec, Matthew Manuel, Michael Recht, Ulrike Reiss, Robert F. Sidonio, Jr., Cristina Tarango, Marijke Van den Berg, Michael Wang, Courtney D. Thornburg

Blood (2022) 140 (Supplement 1): 63–64.

https://doi.org/10.1182/blood-2022-162660

Published: 2022

Journal Articles

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Association between Family History and Age of Diagnosis

Courtney D Thornburg, MD, Kenneth D Friedman, MD, Michael F Guerrera, MD, Chunla He, Lynn M Malec, MD, Mindy L Simpson, MD, Michael D Tarantino, MD, H. Marijke Van Den Berg, Crystal Watson, BS, Shannon L Carpenter, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138748

Published: 2020

Journal Articles

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A

H. Marijke van den Berg, Kathelijn Fischer, Manuel Carcao, Hervé Chambost, Gili Kenet, Karin Kurnik, Chris Königs, Christoph Male, Elena Santagostino, Rolf Ljung

Blood (2019) 134 (3): 317–320.

https://doi.org/10.1182/blood.2019000658

Published: 2019

Includes: Supplemental data

Journal Articles

99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry

Blood (2018) 132 (Supplement 1): 2472.

https://doi.org/10.1182/blood-2018-99-114518

Published: 2018

Journal Articles

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Blood (2016) 128 (22): 3774.

https://doi.org/10.1182/blood.V128.22.3774.3774

Published: 2016

Journal Articles

Can a “center effect” explain the higher frequency of inhibitors for a second-generation recombinant factor VIII product?

H. Marijke van den Berg, Rolf Ljung

Blood (2015) 126 (18): 2164–2165.

https://doi.org/10.1182/blood-2015-08-663583

Published: 2015

Includes: Supplemental data

Journal Articles

Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s

Kathelijn Fischer, Katarina Steen Carlsson, Pia Petrini, Margareta Holmström, Rolf Ljung, H. Marijke van den Berg, Erik Berntorp

Blood (2013) 122 (7): 1129–1136.

https://doi.org/10.1182/blood-2012-12-470898

Published: 2013

Includes: Supplemental data

Journal Articles

Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study

Blood (2013) 121 (20): 4046–4055.

https://doi.org/10.1182/blood-2012-09-457036

Published: 2013

Includes: Supplemental data

Journal Articles

Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A

Blood (2013) 121 (19): 3946–3952.

https://doi.org/10.1182/blood-2012-11-469403

Published: 2013

Includes: Supplemental data

Journal Articles

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

Samantha C. Gouw, H. Marijke van den Berg, Johannes Oldenburg, Jan Astermark, Philip G. de Groot, Maurizio Margaglione, Arthur R. Thompson, Waander van Heerde, Jorien Boekhorst, Connie H. Miller, Saskia le Cessie, Johanna G. van der Bom

Blood (2012) 119 (12): 2922–2934.

https://doi.org/10.1182/blood-2011-09-379453

Published: 2012

Includes: Supplemental data

Journal Articles

Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo

Carina J. van Schooten, Shirin Shahbazi, Evelyn Groot, Beatrijs D. Oortwijn, H. Marijke van den Berg, Cécile V. Denis, Peter J. Lenting

Blood (2008) 112 (5): 1704–1712.

https://doi.org/10.1182/blood-2008-01-133181

Published: 2008

Journal Articles

Response: Immunogenicity of factor VIII concentrates in patients with hemophilia: the next sensible step

Johanna G. van der Bom, Samantha C. Gouw, H. Marijke van den Berg

Blood (2007) 110 (8): 3085.

https://doi.org/10.1182/blood-2007-07-098384

Published: 2007

Journal Articles

Response: Plasma-derived or recombinant factor VIII products and inhibitors in previously untreated patients with severe hemophilia

Johanna G. van der Bom, Samantha C. Gouw, H. Marijke van den Berg

Blood (2007) 110 (3): 1074–1075.

https://doi.org/10.1182/blood-2007-04-084889

Published: 2007

Journal Articles

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study

Samantha C. Gouw, Johanna G. van der Bom, Günter Auerswald, Carmen Escuriola Ettinghausen, Ulf Tedgård, H. Marijke van den Berg

Blood (2007) 109 (11): 4693–4697.

https://doi.org/10.1182/blood-2006-11-056317

Published: 2007

Includes: Supplemental data

Journal Articles

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study

Samantha C. Gouw, Johanna G. van der Bom, H. Marijke van den Berg

Blood (2007) 109 (11): 4648–4654.

https://doi.org/10.1182/blood-2006-11-056291

Published: 2007

Includes: Supplemental data

Journal Articles

O -Linked Glycosylation with Sialylated T-Antigen: A Novel Carbohydrate Determinant of von Willebrand Factor Antigen Levels.

Peter J. Lenting, PhD, Carina J.M. van Schooten, MSc, Ton Lisman, PhD, Marijke van den Berg, MD, PhD, Jeroen C.J. Eikenboom, MD, PhD, Frank W.G. Leebeek, MD, PhD, Jenny Goudemand, MD, PhD, Edith Fressinaud, MD, PhD, Philip G. de Groot, PhD, Cécile V. Denis, PhD

Blood (2006) 108 (11): 178.

https://doi.org/10.1182/blood.V108.11.178.178

Published: 2006

Journal Articles

Factor VIII-Specific Memory B-Cells in Patients with Hemophilia A.

Pauline M.W. van Helden, Paul H.P. Kaijen, H. Marijke van den Berg, Jan Voorberg

Blood (2006) 108 (11): 1020.

https://doi.org/10.1182/blood.V108.11.1020.1020

Published: 2006

Journal Articles

Outcome Assessment in Hemophilia: A Pilot Study on Correlation of Different Instruments.

Kathelijn Fischer, MD, PhD, Frank R. Van Genderen, MSc, PhD, Piet De Kleijn, Marijke Van den Berg, MD, PhD

Blood (2006) 108 (11): 1032.

https://doi.org/10.1182/blood.V108.11.1032.1032

Published: 2006

Journal Articles

Variations in glycosylation of von Willebrand factor with O -linked sialylated T antigen are associated with its plasma levels

Carina J. M. van Schooten, Cécile V. Denis, Ton Lisman, Jeroen C. J. Eikenboom, Frank W. Leebeek, Jenny Goudemand, Edith Fressinaud, H. Marijke van den Berg, Philip G. de Groot, Peter J. Lenting

Blood (2006) 109 (6): 2430–2437.

https://doi.org/10.1182/blood-2006-06-032706

Published: 2006

Journal Articles

Successful treatment of severe bleeding in hemophilic target joints by selective angiographic embolization

Eveline P. Mauser-Bunschoten, Jacco A. C. Zijl, Willem Mali, A. Cees van Rinsum, H. Marijke van den Berg, Goris Roosendaal

Blood (2005) 105 (7): 2654–2657.

https://doi.org/10.1182/blood-2004-06-2063

Published: 2005

NARROW

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Association between Family History and Age of Diagnosis

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A

99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Can a “center effect” explain the higher frequency of inhibitors for a second-generation recombinant factor VIII product?

Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s

Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study

Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo

Response: Immunogenicity of factor VIII concentrates in patients with hemophilia: the next sensible step

Response: Plasma-derived or recombinant factor VIII products and inhibitors in previously untreated patients with severe hemophilia

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study

O -Linked Glycosylation with Sialylated T-Antigen: A Novel Carbohydrate Determinant of von Willebrand Factor Antigen Levels.

Factor VIII-Specific Memory B-Cells in Patients with Hemophilia A.

Outcome Assessment in Hemophilia: A Pilot Study on Correlation of Different Instruments.

Variations in glycosylation of von Willebrand factor with O -linked sialylated T antigen are associated with its plasma levels

Successful treatment of severe bleeding in hemophilic target joints by selective angiographic embolization

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only